SET, Phosphatase 2A Inhibitor I2PP2A

References :
[1] von Lindern M., van Baal S., Wiegant J., Raap A., Hagemeijer A., Grosveld G.; Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3′ half to different genes: characterization of the set gene.;Mol. Cell. Biol. 12:3346-3355(1992).[2] von Lindern M., van Baal S., Wiegant J., Raap A., Hagemeijer A., Grosveld G.;Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3′ half to different genes: characterization of the set gene.;Mol. Cell. Biol. 12:3346-3355(1992).[3] Vaesen M., Barnikol-Watanabe S., Goetz H., Adil Awni L., Cole T., Zimmermann B., Kratzin H.D., Hilschmann N.;Purification and characterization of two putative HLA class II associated proteins: PHAPI and PHAPII.;Biol. Chem. Hoppe-Seyler 375:113-126(1994).[4] Nagata K., Kawase H., Handa H., Yano K., Yamasaki M., Ishimi Y., Okuda A., Kikuchi A., Matsumoto K.;Replication factor encoded by a putative oncogene, set, associated with myeloid leukemogenesis.;Proc. Natl. Acad. Sci. U.S.A. 92:4279-4283(1995).[5] Li M., Makkinje A., Damuni Z.;The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A.;J. Biol. Chem. 271:11059-11062(1996).[6] Tsujio I., Zaidi T., Xu J., Kotula L., Grundke-Iqbal I., Iqbal K.;Inhibitors of protein phosphatase-2A from human brain: structures, immunocytological localization and activities towards dephosphorylation of the Alzheimer type hyperphosphorylated Tau.;Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.[7] The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).;Genome Res. 14:2121-2127(2004).[8] Adachi Y., Pavlaki G.N., Copeland T.D.;Identification and characterization of SET, a nuclear phosphoprotein encoded by the translocation break point in acute undifferentiated leukemia.;J. Biol. Chem. 269:2258-2262(1994).[9] Wang L.C., Chen Y.;A relative factor in human rectum carcinoma.;Submitted (APR-2007) to the EMBL/GenBank/DDBJ databases.[10] Carlson S.G., Eng E., Kim E.-G., Perlman E.J., Copeland T.D., Ballermann B.J.;Expression of SET, an inhibitor of protein phosphatase 2A, in renal development and Wilms’ tumor.;J. Am. Soc. Nephrol. 9:1873-1880(1998).[11] Seo S.-B., McNamara P., Heo S., Turner A., Lane W.S., Chakravarti D.;Regulation of histone acetylation and transcription by INHAT, a human cellular complex containing the Set oncoprotein.;Cell 104:119-130(2001).[12] Minakuchi M., Kakazu N., Gorrin-Rivas M.J., Abe T., Copeland T.D., Ueda K., Adachi Y.; Identification and characterization of SEB, a novel protein that binds to the acute undifferentiated leukemia-associated protein SET.;Eur. J. Biochem. 268:1340-1351(2001).[13] Fan Z., Beresford P.J., Zhang D., Lieberman J.;HMG2 interacts with the nucleosome assembly protein SET and is a target of the cytotoxic T-lymphocyte protease granzyme A.;Mol. Cell. Biol. 22:2810-2820(2002).[14] Fan Z., Beresford P.J., Oh D.Y., Zhang D., Lieberman J.;Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor.;Cell 112:659-672(2003).[15] Fan Z., Beresford P.J., Oh D.Y., Zhang D., Lieberman J.;Cell 115:241-241(2003).[16] Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.;Cell 127:635-648(2006).[17] Sprung R., Chen Y., Xu Y., Ball H., Pei J., Cheng T., Kho Y., Xiao H., Xiao L., Grishin N.V., White M., Yang X.-J., Zhao Y.;Substrate and functional diversity of lysine acetylation revealed by a proteomics survey.;Mol. Cell 23:607-618(2006).[18] Molina H., Horn D.M., Tang N., Mathivanan S., Pandey A.;Global proteomic profiling of phosphopeptides using electron transfer dissociation tandem mass spectrometry.;Proc. Natl. Acad. Sci. U.S.A. 104:2199-2204(2007).